Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.94 -3.55 (-2.74%)
Streaming Delayed Price Updated: 2:45 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
66 67 Next >
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Cannabis Industry's Capital Crunch: Why It Needs More Funds Than Other Industries, Will Fed Legalization Change This?
Recent research conducted by Viridian Capital Advisors reveals that the cannabis sector requires more capital as compared to other similar industries. 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Steady Eddies: 7 Unshakeable Stocks for Any Type of Market
With economic circumstances treading in uncertain waters, investors may want the confidence of safe stocks to buy. 
Via InvestorPlace
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors.
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors. 
Via Chartmill
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
What 7 Analyst Ratings Have To Say About Merck & Co
Via Benzinga
Better Pharma Growth Stock: Eli Lilly vs. Merck
This is a close contest, but there's a clear winner. 
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Check Out What Whales Are Doing With MRK
Via Benzinga
Viridian Chart Of The Week: How Capital Intensive Is Cannabis?
The chart explores the capital intensity of cannabis compared to four other industries thought to be likely suitors for cannabis companies upon federal legalization: Tobacco, Alcoholic Beverages,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
Some of the most frequently prescribed medications in the U.S. might soon become more affordable. 
Via Benzinga
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck... 
Via Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market
The company inked a new deal on Monday to test a new regimen using a second cancer vaccine. 
Via Investor's Business Daily
Moderna Teams Up With Chinese Biotech To Assess Cell-Based Therapy And Cancer Vaccine Combo
A Chinese biotech, CARsgen Therapeutics and Moderna Inc (NASDAQ: MRNA) have collaborated 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023
These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development. 
Via InvestorPlace
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients
Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible  
Via Benzinga
Federal Court Rules To Prohibit Access To Abortion Pill: Supreme Court To Weigh In
The 5th Circuit Court of Appeals ruled Wednesday to prohibit access to mifepristone, the drug known as the abortion pill, in a case filed against the Food and Drug Administration. 
Via Benzinga
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
These undervalued penny stocks each provide big upside potential, while trading with relatively high margins of safety. 
Via InvestorPlace
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare
Healthcare stocks are starting to shine in 2023 after bottoming out and MRK stock is particularly appealing. Here's why. 
Via InvestorPlace
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
The 3 Best ESG Stocks to Buy in August
Although doing right would seem to come at a cost to shareholder profit potential, these best ESG stocks to buy prove otherwise. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.